TABLE 1.
Clinical and biological characteristics at the time of transplantation.
| Variables | Whole Cohort, N = 115 | Late Switch, N = 77 | Early Switch, N = 38 |
|---|---|---|---|
| Recipient characteristics | |||
| Age, mean ± SD | 55.8 (15.0) | 53.9 (15.0) | 60.0 (14.3) |
| Gender (Male), N (%) | 76 (66.1) | 51 (66.2) | 25 (65.8) |
| Hemodialysis, N (%) | 106 (92.2) | 74 (96.1) | 32 (84.2) |
| Previous KT, N (%) | 15 (13.0) | 13 (16.9) | 2 (5.3) |
| Initial nephropathy | |||
| Glomerulopathy, N (%) | 24 (20.9) | 15 (19.5) | 9 (23.7) |
| Diabetes mellitus, N (%) | 18 (15.7) | 9 (11.7) | 9 (23.7) |
| Nephroangiosclerosis, N (%) | 11 (9.6) | 8 (10.4) | 3 (7.9) |
| Genetic, N (%) | 10 (8.7) | 8 (10.4) | 2 (5.3) |
| Autoimmune disease, N (%) | 4 (3.5) | 3 (3.9) | 1 (2.6) |
| Other, N (%) | 22 (19.1) | 15 (19.5) | 7 (18.4) |
| Undetermined, N (%) | 26 (22.6) | 19 (24.7) | 7 (18.4) |
| Donor | |||
| Age, mean ± SD | 61.5 (15) | 60.6 (14.29) | 63.4 (16.39) |
| Living donor, N (%) | 7 (6.1) | 5 (6.5) | 2 (5.3) |
| Extended criteria donor, N (%) | 69 (60) | 46 (59.7) | 23 (60.5) |
| Donor/recipient CMV status | |||
| D+/R+, N (%) | 51 (44.3) | 36 (48.8) | 15 (39.5) |
| D+/R-, N (%) | 22 (19.1) | 16 (20.8) | 6 (15.8) |
| D-/R+, N (%) | 34 (29.6) | 21 (27.3) | 13 (34.2) |
| D-/R-, N (%) | 8 (7) | 4 (5.2) | 4 (10.5) |
| Kidney transplant characteristics | |||
| Anti HLA donor specific antibodies, N (%) | 11 (9.8) | 6 (7.9) | 5 (13.9) |
| Cold ischemia time, hours N = 112, N (%) | 18.1 (5.7) | 18.2 (5.5) | 17.7 (6) |
| Delayed graft function, N (%) | 51 (44.3) | 31 (40.3) | 20 (52.6) |
| Induction immunosuppressive therapy | |||
| Anti-interleukin 2 receptor, N (%) | 61 (53) | 42 (54.5) | 19 (50) |
| Antithymocyte globulin, N (%) | 54 (47) | 35 (45.5) | 19 (50) |
| Maintenance immunosuppressive therapy | |||
| Calcineurin inhibitors, N (%) | |||
| Cyclosporine | 20 (17.4) | 16 (20.8) | 4 (10.5) |
| Tacrolimus | 95 (82.6) | 61 (79.2) | 34 (89.5) |
| Mycophenolic acid (MPA), N (%) | 95 (82.6) | 66 (85.7) | 29 (76.3) |
| mTOR inhibitors, N (%) | 19 (16.5) | 11 (14.3) | 8 (21.1) |
| Steroids | 115 (100) | 77 (100) | 38 (100) |
KT, Kidney transplantation; mTOR, Mammalian target of rapamycin.